Analysts Issue Forecasts for REGN FY2025 Earnings

Key Points

• Investment firm Cantor Fitzgerald raised its FY2025 EPS estimate for Regeneron Pharmaceuticals to $30.25 from a previous estimate of $26.31, maintaining an "Overweight" rating and a target price of $695.00.
• Regeneron reported a quarterly EPS of $12.89 for the last quarter, surpassing the consensus estimate of $8.43, with revenue of approximately $3.68 billion.
• The company announced a quarterly dividend of $0.88 per share, resulting in an annualized dividend yield of 0.6%.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) - Equities research analysts at Cantor Fitzgerald increased their FY2025 earnings per share estimates for shares of Regeneron Pharmaceuticals in a research note issued on Wednesday, August 13th. Cantor Fitzgerald analyst C. Gould now forecasts that the biopharmaceutical company will post earnings of $30.25 per share for the year, up from their previous forecast of $26.31. Cantor Fitzgerald has a "Overweight" rating and a $695.00 price objective on the stock. The consensus estimate for Regeneron Pharmaceuticals' current full-year earnings is $35.92 per share. Cantor Fitzgerald also issued estimates for Regeneron Pharmaceuticals' FY2026 earnings at $30.33 EPS.

Several other analysts have also weighed in on the company. Robert W. Baird cut their price objective on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a report on Friday, April 25th. Citigroup reaffirmed a "buy" rating and set a $650.00 target price on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Rothschild & Co Redburn started coverage on Regeneron Pharmaceuticals in a research report on Thursday. They set a "buy" rating and a $890.00 target price on the stock. Morgan Stanley reaffirmed an "overweight" rating and set a $761.00 target price (up from $754.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Finally, The Goldman Sachs Group cut their target price on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating on the stock in a research report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, seventeen have given a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $838.00.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock traded down $6.50 during trading on Friday, hitting $573.91. The stock had a trading volume of 768,031 shares, compared to its average volume of 976,576. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. The firm has a market cap of $60.83 billion, a P/E ratio of 14.46, a PEG ratio of 1.93 and a beta of 0.33. The business has a fifty day moving average of $545.33 and a two-hundred day moving average of $593.59. Regeneron Pharmaceuticals has a fifty-two week low of $476.49 and a fifty-two week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%. The firm had revenue of $3,675,600 billion during the quarter, compared to the consensus estimate of $3.30 billion. During the same period in the prior year, the business earned $11.56 EPS. The firm's revenue was up 3.6% on a year-over-year basis.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of large investors have recently modified their holdings of the business. Geneos Wealth Management Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 3.0% in the 2nd quarter. Geneos Wealth Management Inc. now owns 780 shares of the biopharmaceutical company's stock valued at $410,000 after purchasing an additional 23 shares in the last quarter. Westwood Holdings Group Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 17.0% in the 2nd quarter. Westwood Holdings Group Inc. now owns 13,556 shares of the biopharmaceutical company's stock valued at $7,117,000 after purchasing an additional 1,974 shares in the last quarter. CYBER HORNET ETFs LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at $144,000. Rexford Capital Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at $143,000. Finally, Evergreen Capital Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 109.6% in the 2nd quarter. Evergreen Capital Management LLC now owns 8,134 shares of the biopharmaceutical company's stock valued at $4,270,000 after purchasing an additional 4,253 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.